瑞格列奈与罗格列酮联合治疗2型糖尿病临床观察

【目的】观察瑞格列奈与罗格列酮联合治疗2型糖尿痛对早期胰岛素分泌相的影响。【方法】70例初诊2型糖尿病患者，分为单纯口服瑞格列奈33例（治疗组）．瑞格列奈和罗格列酮联合治疗37例（强化组）。比较治疗前后两组患者空腹血糖、餐后2h时血糖、糖化血红蛋白、餐后1h、2h血浆胰岛素的变化。【结果】治疗组餐后2h血糖较治疗前明显下降（P〈0．05）。餐后1h血浆胰岛素明显升高（P〈0．05）；强化组治疗后空腹血糖，餐后2h血糖较治疗前明显下降（P〈0．05），餐后1h血浆胰岛素显著升高（P〈0．01），餐后2h血浆胰岛素降低。且餐后2h血浆胰岛素显著低于餐后1h血浆胰岛素（P〈0．05）。【结论】瑞格列奈可改善胰岛素早期分泌时相，但恢复时相峰值困难，瑞格列奈与罗格列奈联合治疗可使2型糖尿病胰岛素早期分泌相恢复，餐后血糖控制更好。

Clinical Observation of the Therapeutic Alliance of Repaglinide and Rosiglitazone in Type 2 Diabetes

[Objective]To observe the effect of the firstphase insulin secretion in therapeutic alliance of Repaglinide and Rosiglitazone type 2 diabetes. [Methods]Seventy patients with preliminary diagnosis type 2 diabetes were enrolled in this study, in which 33 patients received Repaglinide (trial)and 37 patients received Repaglinide and Rosiglitazone(augmentation),The changes of the fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG),HbA1c levels,1-hour plasmic insulin, 2-hour plasmic insulin were compared with the baseline.[Results]Repaglinide visibly reduced PBG(P<0.05),It significantly increased 1-hour plasmic insulin(P<0.05). Repaglinide and Rosiglitazone visibly reduced FBG and PBG(P<0.05,P<0.01), they significantly increased 1-hour plasmic insulin(P<0.01)and reduced 2-hour plasmic insulin, 2-hour plasmic insulin were significantly lower than 1-hour plasmic insulin(P<0.05).[Conclusion]Repaglinide may improve the early insulin release,but full recovery of the phase peak amplitude is difficult , the therapeutic alliance of Repaglinide and Rosiglitazone may recover the early insulin release and PBG may be better controled.